Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$138.98 USD

138.98
274,449

+1.26 (0.92%)

Updated Jul 17, 2024 02:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock.

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Align (ALGN) Debuts Invisalign Palatal Expander in New Markets

by Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.

Veeva Systems (VEEV) Makes Change to Front Office (revised)

by Zacks Equity Research

Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

by Zacks Equity Research

QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.

Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

by Zacks Equity Research

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop

by Zacks Equity Research

Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

by Zacks Equity Research

Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

AngioDynamics (ANGO) Settles Patent Litigations With BD

by Zacks Equity Research

AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes

by Zacks Equity Research

Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.

Thermo Fisher (TMO) Debuts a New In-Line Metrology Solution

by Zacks Equity Research

Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).

Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

by Zacks Equity Research

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

by Zacks Equity Research

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Tandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

by Zacks Equity Research

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.